A phase 1 trial of SAN2355
Latest Information Update: 17 Mar 2025
At a glance
- Drugs SAN 2355 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- 17 Mar 2025 New trial record
- 03 Mar 2025 According to a Saniona media release, company plans to file a clinical trial application around year-end 2025